.Nature Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a median follow-up of 11 months, people along with metastatic intestinal lumps that got biomarker-matched treatments based on flowing lump DNA profiling revealed a greater professional advantage than those receiving unequaled treatment.